Potency and timing of antiviral therapy as determinants of duration of SARS CoV-2 shedding and intensity of inflammatory response

Ashish Goyal; E. Fabian Cardozo-Ojeda; Joshua T Schiffer

is the (which was not peer-reviewed) The copyright holder for this preprint . https://doi.org/10.1101/2020.04. 10.20061325 doi: medRxiv preprint Figure 6 . Projections of remdesivir drug resistance during therapy. Simulations are with high potency (EC50=0.8 uM) and the assumption that mutants confer partial drug resistance. Treatment initiation is at timepoints generally consistent with hospitalization (day 10 after first positive sample), first symptoms (day 5 after first positive sample), pre-symptomatic post-peak phase (day 2 after first positive sample) or pre-symptomatic pre-peak phase (day 0). A. Projections of no treatment, treatment with no assumed drug resistance, and treatment with assumed drug resistance. B. Projections of assumed drug resistance with trajectories of sensitive strains, single mutants and double mutants.